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Concordance of cribriform architecture in matched prostate cancer biopsy and radical
prostatectomy specimens
Aims: Invasive cribriform and/or intraductal carci-
noma have been identified as independent adverse
parameters for prostate cancer outcome. Little is
known on biopsy undersampling of cribriform archi-
tecture. Our aim was to determine the extent of crib-
riform architecture undersampling and to find
predictive factors for identifying false cribriform-nega-
tive cases.
Methods and results: We reviewed 186 matched pros-
tate biopsies and radical prostatectomy specimens. Of
97 biopsy grade group 2 (Gleason score 3 + 4 = 7)
patients, 22 (23%) had true cribriform-negative (TN),
39 (40%) false-negative (FN) and 36 (37%) true-posi-
tive (TP) biopsies. Patients with FN biopsies had
higher, although not statistically significant
(P = 0.06), median PSA levels than patients with TP
biopsies (12 versus 8 ng/ml). A PI-RADS 5 lesion
was present in nine of 16 (54%) FN and three of 11
(27%) TN biopsies (P = 0.05). Positive biopsy rate
(P = 0.47), percentage Gleason pattern 4 (P = 0.55)
and glomeruloid architecture (P = 1.0) were not dif-
ferent. Logistic regression identified PSA as an inde-
pendent predictor (odds ratio = 3.5; 95% confidence
interval = 1.2–9.4, P = 0.02) for cribriform architec-
ture on radical prostatectomy, but not PI-RADS score.
The FN rate for large cribriform architecture at radi-
cal prostatectomy was 27%, which was lower than
for any cribriform architecture (P = 0.01). During fol-
low-up (median 27 months), biochemical recurrence-
free survival of patients with TP biopsies was signifi-
cantly shorter than that of those with FN biopsies
(P = 0.03).
Conclusion: In conclusion, 40% of grade group 2
prostate cancer biopsies were FN for cribriform archi-
tecture. These patients had higher PSA levels and
more frequent PI-RADS score 5 lesions than men
with TN biopsies.
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Introduction
Risk stratification and therapeutic decision-making in
prostate cancer patients is affected by potential biopsy
undersampling. The Gleason score is one of the most
important parameters for predicting disease outcome
and guiding individual treatment. Men with Gleason
score 3 + 3 = 6 (International Society of Urological
Pathology (ISUP) grade group 1] prostate cancer are
eligible for active surveillance, whereas men with
Gleason score ≥4 + 3 = 7 (grade groups 3–5) are
usually treated with radical prostatectomy, radiation
therapy and/or hormonal therapy. The optimal thera-
peutic strategy for men with Gleason score 3 + 4 = 7
(grade group 2) is still a matter of debate. While most
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of these patients will undergo active treatment,
surveillance is increasingly being considered in this
subgroup. Incorporation of additional clinicopatholog-
ical and molecular parameters might be able to sup-
port optimal decision-making in this large prostate
cancer subpopulation.
Grade group 2 prostate cancer is a heterogeneous
disease with variable architectural growth patterns
and Gleason pattern 4 quantities. While individual
growth patterns are not routinely mentioned in
pathology reports, recent studies have shown that
patients with cribriform architecture have an adverse
outcome compared to those without.1–3 Both invasive
and intraductal cribriform architecture have been
associated with adverse clinicopathological character-
istics, post-operative recurrence rates, metastasis and
disease-specific death.4–8 Conversely, biopsy grade
group 2 prostate cancer patients without cribriform
architecture have comparable disease-specific survival
and post-operative biochemical recurrence rates to
men with grade group 1 disease.1,19 Quantification of
Gleason pattern 4 can further add in risk stratifica-
tion, as post-operative biochemical recurrence rates
increment with a higher Gleason pattern 4 tumour
percentage.10 Cribriform architecture and Gleason
pattern 4 quantification might therefore be important
adjuncts in risk stratification of grade group 2 pros-
tate cancer patients.
While pathological tumour characteristics are
important for clinical decision-making, prostate biop-
sies are prone to undersampling. Prostate cancer is
up-graded in up to 40% of subsequent radical prosta-
tectomy specimens.11,12 At present, little is known on
the extent of undersampling in detection of cribriform
architecture or Gleason pattern 4 percentage. The
aim of our study is to determine the extent of under-
sampling for the detection of cribriform architecture
in matched prostate biopsy and radical prostatectomy
specimens, and to identify potential factors for dis-
criminating true- from false cribriform-negative pros-
tate biopsies.
Materials and methods
P A T I E N T S E L E C T I O N
We identified 186 patients who had undergone
both biopsy and subsequent radical prostatectomy
at Erasmus MC University Medical Center, Rotter-
dam, the Netherlands between 2010 and 2017.
Biopsies were prompted by elevated prostate-specific
antigen (PSA) levels or obtained in the scope of
active surveillance. The Prostate Imaging Reporting
and Data System (PI-RADS) score was annotated
by an expert uroradiologist, when patients had
received multiparametric magnetic resonance imag-
ing (MRI).13 When suspicious lesions (PI-RADS 3–
5) were visible on MRI, targeted MRI-ultrasound
fusion biopsies were taken. Individual biopsy cores
were enclosed in separate containers and radical
prostatectomy specimens were completely embedded
for diagnostic purposes. All slides of both biopsies
and radical prostatectomies were available for
pathological review. This study was approved by
the institutional Medical Research Ethics Committee
(MEC-2018-1614).
P A T H O L O G I C A L E V A L U A T I O N
All biopsies were reviewed by three investigators,
who were blinded to clinical outcome and radical
prostatectomy characteristics. For each biopsy core
the following features were recorded: Gleason score,
grade groups according to the World Health Organi-
sation (WHO)/ISUP 2014 guidelines, maximal single
biopsy tumour length (mm), overall estimated per-
centage Gleason pattern 4 and individual tumour
growth patterns.14 Invasive cribriform Gleason pat-
tern 4 was not distinguished from intraductal carci-
noma because of their significant morphological
overlap, which would require extensive immunohis-
tochemical staining for further discrimination.1 If tar-
geted biopsies were obtained, these were considered
as separate biopsies and not as one single biopsy.
Matching radical prostatectomy specimens were eval-
uated as described previously.4 We recorded Gleason
score, grade group, pT-stage according to the AJCC
TNM 8th edition, surgical margin status, percentage
Gleason pattern 4 and individual growth patterns.15
Furthermore, we distinguished small and large
expansive cribriform growth pattern based on a cut-
off of two times the size of adjacent pre-existent nor-
mal glands.4
C L I N I C A L F O L L O W - U P
After radical prostatectomy, clinical follow-up con-
sisted of bi-annual, and later annual monitoring of
serum PSA levels. Biochemical recurrence was
defined as PSA levels ≥0.2 ng/ml measured at two
consecutive time-points at least 3 months apart with
undetectable PSA levels after operation, or as PSA
increase of >2.0 ng/ml when serum PSA had not
declined to zero after operation. Survival was defined
as time in months from radical prostatectomy to bio-
chemical recurrence or last follow-up.
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S T A T I S T I C A L A N A L Y S I S
Continuous variables with normal distribution were
compared by Student’s t-test and one-way analysis of
variance (ANOVA) and those without normal distribu-
tion with the Mann–Whitney U-test. For categorical
parameters, 2 or Fisher’s exact were used. Correlation
between continuous variables was analysed using
Pearson’s correlation coefficient. Dichotomous out-
come variables were analysed using logistic regres-
sion. Survival was visualised by Kaplan–Meier curves.
Statistics were performed using R version 3.2.2 (R
Foundation for Statistical Computing, Vienna, Aus-
tria) and results were considered significant when the
two-sided P-value was <0.05.
Results
C L I N I C O P A T H O L O G I C A L C H A R A C T E R I S T I C S
The entire cohort consisted of 186 patients with
matched biopsy and radical prostatectomy specimens.
The mean age at time of operation was 65 years [in-
terquartile range (IQR) = 62–70] and the mean PSA
level was 12 ng/ml (IQR = 6–15). In total, 144
(77%) patients underwent systematic biopsies, 26
(14%) received systematic and targeted biopsies and
16 (9%) had targeted biopsies only. The mean num-
ber of biopsies taken was nine (IQR = 8–10), with
four (IQR = 3–5) biopsies containing adenocarci-
noma, representing 49% (IQR = 30–66) of the total
number of biopsy cores. Fifty (27%) patients had
overall biopsy grade group 1, 99 (53%) grade group
2, 11 (6%) grade group 3, 15 (8%) grade group 4
and 11 (6%) grade group 5.
On radical prostatectomy, 87 (47%) adenocarcino-
mas were pT2, 76 (41%) pT3a and 23 (12%) pT3b.
Distribution of the grade groups on radical prostatec-
tomy was as follows: 19 (10%) grade group 1, 108
(58%) grade group 2, 25 (14%) grade group 3, 17
(9%) grade group 4 and 17 (9%) grade group 5.
Tumour up-grading occurred in 65 (35%) and down-
grading in 14 (8%) radical prostatectomies, while
107 (57%) cases had concordant tumour grades. Pos-
itive surgical margins were present in 63 (34%)
patients. Eighty patients had simultaneously under-
gone pelvic lymph node dissection, 18 of which
(23%) contained lymph node metastasis. The mean
post-operative follow-up was 32 months (me-
dian = 22, IQR = 8–51).
Invasive cribriform and/or intraductal carcinoma
was observed in 57 (31%) diagnostic biopsies and in
128 (69%) radical prostatectomy specimens (Table 1).
Cribriform architecture was present in both matched
biopsy and radical prostatectomy specimens in 55
(30%) and absent in 56 (30%) cases. In 73 (39%)
men cribriform architecture was observed in the radi-
cal prostatectomy specimen, but not in preceding
biopsies. Two cases (1%) had cribriform architecture
at biopsy but not at subsequent radical prostatec-
tomy, which is probably due to sampling error, and
these were excluded from further analyses. Therefore,
the sensitivity for cribriform architecture on biopsies
was 43%, while specificity was 97%. Cribriform archi-
tecture was observed more frequently in targeted (19
of 40; 48%) than systematic biopsies (36 of 144;
25%, P = 0.01).
C O N C O R D A N C E O F C R I B R I F O R M A R C H I T E C T U R E
I N G R A D E G R O U P 2 P R O S T A T E C A N C E R B I O P S I E S
Because cribriform architecture might be most rele-
vant for treatment decisions in patients with biopsy
grade group 2 prostate cancer, we performed further
analyses within this subgroup (n = 97). Thirty-six
(37%) patients with biopsy grade group 2 demon-
strated cribriform architecture on both matched
biopsy and radical prostatectomy specimen (true crib-
riform-positive, CR+/CR+), while cribriform architec-
ture was absent in both specimens in 22 (23%) cases
(true cribriform-negative, CR/CR). In 39 (40%)
patients, cribriform architecture was present on radi-
cal prostatectomy but not on preceding biopsy; these
patients were considered as having false cribriform-
negative (CR/CR+) biopsies. None of the patients
with biopsy grade group 2 had cribriform architec-
ture on biopsy, while radical prostatectomy was neg-
ative for cribriform architecture.
I D E N T I F I C A T I O N O F P R E D I C T O R S I N T R U E - A N D
F A L S E C R I B R I F O R M - N E G A T I V E G R A D E G R O U P 2
P R O S T A T E C A N C E R B I O P S I E S
Patients with true-negative biopsies were slightly
younger (62 versus 65 years, P = 0.06) and had
Table 1. Prevalence of invasive cribriform and/or intraduc-
tal carcinoma (CR/IDC) in biopsies and matched radical
prostatectomies
Radical prostatectomy
Prostate biopsy CR/IDC CR/IDC+
CR/IDC 56 (30%) 73 (39%)
CR/IDC+ 2 (1%) 55 (30%)
© 2019 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 75, 338–345.
340 E Hollemans et al.
lower PSA levels (8 versus 12 ng/ml, P = 0.06) than
men with false-negative biopsies; however, these dif-
ferences were not significant (Table 2). In total, 51
patients (53%) had undergone multiparametric MRI
prior to biopsy. Of 11 patients with true-negative
biopsies, three (27%) had a PI-RADS 5 lesion com-
pared to nine of 16 (56%) false-negative and 17 of
24 (71%) true-positive biopsy patients (P = 0.05).
The number of biopsies (P = 0.53), percentage of pos-
itive biopsies (P = 0.47) and maximal tumour length
(P = 0.44) were not different between true- and false-
negative biopsies. As Gleason pattern 4 percentage
and glomeruloid architecture have both been associ-
ated with cribriform architecture, we assessed the
predictive value of these pathological parameters.8,16
Mean percentage of Gleason pattern 4 was 12%
(IQR = 5–10%) in true-negative biopsies and 11%
(IQR = 5–16%) in false-negative biopsies (P = 0.55).
There was only a weak correlation between percent-
age Gleason pattern 4 on biopsies (mean = 13%,
IQR = 5–20%) and matched radical prostatectomies
(mean = 31%, IQR = 10–40%, R2 = 0.093;
P = 0.001). Glomeruloid growth pattern was encoun-
tered in six of 22 (27%) true-negative and 11 of 39
(28%) false-negative biopsies (P = 1.0).
Logistic regression analysis on cribriform-negative
biopsy patients showed that age [odds ratio
(OR) = 1.1, 95% confidence interval (CI) = 1.0–1.3,
P = 0.02] and PSA (OR = 3.3, 95% CI = 1.2–9.1,
P = 0.02) were independent predictive parameters for
presence of cribriform architecture on radical prosta-
tectomy in multivariable analysis, whereas PI-RADS
score, number and percentage of positive biopsies,
maximal tumour length, presence of targeted biopsies
and percentage Gleason grade 4 were not (Table 3).
C O M P A R I S O N O F F A L S E - N E G A T I V E A N D T R U E
C R I B R I F O R M - P O S I T I V E G R A D E G R O U P 2 B I O P S I E S
PSA levels of men with true-positive biopsies were
slightly higher than of those with false-negative biop-
sies, but this was not statistically significant (16 ver-
sus 12 ng/ml, P = 0.13). Patients with true-positive
biopsies had a significantly higher total number of
biopsies (10 versus 8, P = 0.02) and number of
tumour-positive biopsies (6 versus 4, P = 0.001);
however, no differences were seen in percentage of
positive biopsies (59 versus 52%, P = 0.19) when
compared to patients with false-negative biopsies. The
percentage of Gleason pattern 4 was higher in
patients with cribriform-positive biopsies than in
those with false-negative biopsies (17 versus 11%,
P = 0.03). Final grade group (P = 0.97), pT stage
(P = 0.27) and surgical margin status (P = 0.24) of
the radical prostatectomy specimens were not differ-
ent between these two groups. The tumour volume
percentage of cribriform growth at radical prostatec-
tomy was higher in patients with true-positive biop-
sies than in those with false-negative biopsies, but
this did not meet conventional measures of signifi-
cance (13% versus 6%, P = 0.06).
Large expansile cribriform architecture, which rep-
resents an aggressive subtype of invasive cribriform
carcinoma, was present in 22 of 97 (23%) radical
prostatectomy specimens.4 Sixteen of these 22 (73%)
patients had any size cribriform fields on biopsy,
while biopsies were false-negative in six (27%) men.
The false-negative rate for more aggressive large crib-
riform architecture (six of 22; 27%) was lower than
for any cribriform architecture (39 of 75; 52%,
P = 0.01). If large cribriform carcinoma was present
at radical prostatectomy, the tumour volume percent-
age of any cribriform growth in the operation speci-
mens did not differ between men with false
cribriform-negative and true-positive biopsies
(P = 0.5). This indicates that the lower false-negative
rate of large cribriform growth was not merely due to
a larger total cribriform tumour percentage at radical
prostatectomy.
C L I N I C O P A T H O L O G I C A L O U T C O M E I N G R A D E
G R O U P 2 P A T I E N T S
Of 97 patients with biopsy grade group 2 prostate
cancer, 73 (75%) had concordant grade group at rad-
ical prostatectomy, 20 (21%) were up-graded to
grade groups 3 to 5 and four (4%) down-graded to
grade group 1. Up-grading occurred in nine of 36
(25%) true-positive and in nine of 39 (23%) false-
negative biopsies, and was significantly lower
(P = 0.01) in true-negative biopsies (two of 22, 9%).
Extraprostatic expansion and surgical margins status
were not significantly different between the three
groups.
Biochemical recurrence occurred in 21 (22%)
patients and was significantly more frequent in the
true-positive (13 of 36, 36%) than in the false-nega-
tive group (six of 39, 15%, P = 0.03). The true-nega-
tive group (two of 22, 9%) showed the lowest
incidence of biochemical recurrence; however, this
difference was not significant (P = 0.13) when com-
pared to the false-negative group.
The median post-operative follow-up of grade group
2 patients was 27 months (mean = 18, IQR = 6–40).
Patients experienced biochemical recurrence after a
median of 14 months (mean = 24, IQR = 5–32).
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Table 2. Characteristics of biopsy grade group 2 prostate cancer (PCa) patients stratified for true cribriform-negative (CR/
CR), false cribriform-negative (CR/CR+) and true cribriform-positive (CR+/CR+) biopsies
CR/CR (n = 22) CR/CR+ (n = 39) CR+/CR+ (n = 36) P-value
Age (years) 62 (63, 58–65) 65 (66, 62–71) 66 (66, 62–71) 0.06†
PSA 8 (8, 6–10) 12 (10, 6–17) 16 (13, 9–19) 0.06‡
PI-RADS score
No MRI 11 (50%) 23 (59%) 12 (33%) 0.10§
1–2 3 (14%) 0 (0%) 0 (0%)
3 1 (5%) 1 (3%) 2 (6%)
4 4 (18%) 6 (15%) 5 (14%)
5 3 (14%) 9 (23%) 17 (47%)
Number of biopsies 9 (9, 8–10) 8 (8, 7–10) 10 (10, 8–12) 0.53–
Number PCa-positive biopsies 4 (3, 2–6) 4 (4, 3–5) 6 (5, 4–8) 0.64–
Percentage PCa-positive biopsies 47 (38, 25–71) 52 (50, 31–73) 59 (61, 40–76) 0.47–
Maximal tumour length (mm) 7 (7, 5–8) 8 (7, 5–10) 9 (10, 7–12) 0.44–
Percentage Gleason pattern 4 12 (8, 5–10) 11 (8, 5–16) 17 (15, 7–23) 0.55†
Presence of glomeruloid growth 6 (27%) 11 (28%) 12 (33%) 1.0††
Presence of large cribriform growth 0 6 (15%) 16 (44%) NA
Presence of targeted biopsies 2 (9%) 8 (20%) 13 (36%) 0.30††
ISUP grade on radical prostatectomy
1 2 (9%) 1 (3%) 1 (3%) 0.01††
2 18 (82%) 29 (74%) 26 (72%)
3 0 (0%) 8 (20%) 7 (19%)
4 0 (0%) 1 (3%) 1 (3%)
5 2 (9%) 0 (0%) 1 (3%)
Positive surgical margins 8 (36%) 12 (31%) 12 (33%) 0.78§
pT stage (TNM 8th)
2 11 (50%) 15 (38%) 17 (47%) 0.66§
3a 10 (45%) 20 (51%) 12 (33%)
3b 1 (5%) 4 (11%) 7 (20%)
Biochemical recurrence 2 (9%) 6 (15%) 13 (36%) 0.69††
Metastasis 0 (0%) 1 (3%) 4 (11%) NA
Mean (median, interquartile range) or n (%).
NA, not applicable; PSA, prostate-specific antigen; MRI, magnetic resonance imaging; PI-RADS, Prostate Imaging Reporting and Data System.
†Wilcox-test
‡t-test (log2 values were used for this test)
§v2.
–one-way analysis of variance (ANOVA)
††Fisher’s test. P-values resemble comparison between CR/CR and CR/CR+.
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Biochemical recurrence-free survival was not signifi-
cantly different between patients with true-negative
and false-negative biopsies (log-rank P = 0.55).
Patients with cribriform-positive biopsies had signifi-
cantly shorter biochemical recurrence-free survival
than men with false-negative biopsies (log-rank
P = 0.03, Figure 1).
Discussion
Identification and pathological reporting of invasive
cribriform and/or intraductal carcinoma of the pros-
tate are increasingly important, as they are both
associated with adverse clinical outcome.1,2,5,6 Biopsy
undersampling is a well-known problem which might
have a significant impact on individual patient man-
agement.11,17,18 Hitherto, little is known about biopsy
undersampling in identifying cribriform architecture.
In this study we demonstrated that biopsies were
false-negative for cribriform architecture in 39% of all
cases and in 40% of patients with biopsy grade group
2 prostate cancer. In false-negative grade group 2
patients, age and PSA level were independent predic-
tive parameters for the presence of cribriform archi-
tecture on subsequent radical prostatectomy, while
the percentage of positive biopsies, maximal biopsy
tumour length, percentage Gleason pattern 4 and
glomeruloid growth were not. Patients with the more
aggressive large cribriform growth pattern on radical
prostatectomy were, however, less likely to have crib-
riform-negative biopsies.4 Biopsy grade group 2
patients with false cribriform-negative biopsies
showed better biochemical recurrence-free survival
rates than men with true cribriform-positive biopsies,
although follow-up was relatively short.
Table 3. Logistic regression analysis of biopsy grade group 2 cribriform-negative prostate cancer (PCa) patients (n = 61),
predicting cribriform architecture on radical prostatectomy
Univariate Multivariable
OR 95% CI P-value OR 95% CI P-value
Age (years) 1.1 1.0–1.2 0.06 1.1 1.0–1.3 0.02
PSA (log2) 2.2† 1.0–4.8 0.04 3.3† 1.2–9.1 0.02
PI-RADS score
<5 Ref.
5 1.9 0.5–7.9 0.38 1.8 0.3–9.1 0.49
Number of biopsies 0.9 0.8–1.1 0.53 0.8 0.6–1.1 0.21
Percentage of PCa-positive biopsies 2.1 0.3–15 0.47 0.2 0.0–5.5 0.35
Maximal tumour length (mm) 1.1 0.9–1.2 0.43 1.0 0.9–1.3 0.70
Percentage of Gleason pattern 4 1.0 0.9–1.0 0.70 1.0 0.9–1.0 0.36
Presence of targeted biopsies
No Ref.
Yes 2.6 0.5–13 0.26 1.1 0.1–10 0.91
OR, odds ratio; CI, confidence interval; PI-RADS, Prostate Imaging Reporting and Data System.
†Per doubling unit.
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Figure 1. Biochemical recurrence-free survival of biopsy grade
group 2 prostate cancer patients, stratified for the presence of crib-
riform architecture on biopsies and subsequent radical prostatec-
tomies (log-rank over all groups, P-value = 0.02).
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Masoomian et al.19 studied concordance rates of
cribriform architecture in 245 matched biopsies and
operation specimens and found a relatively low sensi-
tivity of 47%, corresponding well with the 43% sensi-
tivity in our study. In their subset of grade group 2
biopsy patients, false-negative and true-positive biop-
sies both had a more advanced stage compared to
true-negative biopsies on radical prostatectomy, sug-
gesting that men with false-negative and true-positive
biopsies have a comparable outcome. This contrasts
with our study, as we found that post-operative bio-
chemical recurrence-free survival of men with true-
positive biopsies was significantly shorter than of
those with false-negative biopsies. The difference
might be explained by the different and relatively
small cohorts in both studies.
While most patients with biopsy grade group 2
prostate cancer undergo active treatment, the ques-
tion arises as to whether surveillance could be a safe
alternative for subgroups of this large patient popula-
tion. It has, for instance, been proposed that patients
with biopsy grade group 2 prostate cancer and low
Gleason pattern 4 percentage should be considered
for surveillance.20,21 Others have suggested that
biopsy grade group 2 prostate cancer patients with-
out invasive cribriform and/or intraductal carcinoma
might be eligible for surveillance.7,9 To further sup-
port clinical decision tools, it is important to gain
insight into the false-negative rate of potentially
aggressive disease parameters and to determine how
this rate can be minimised to an acceptable level. In
the current study, we showed that consideration of
PSA level, which is an important parameter for active
surveillance, might prevent men with potentially
aggressive false-negative biopsies from being
abstained from immediate treatment. Furthermore,
presence of a PI-RADS 5 lesion on multiparametric
MRI might also be indicative of more aggressive dis-
ease. Truong et al.22 identified cribriform morphology
in combined systematic and targeted biopsies in 37%
of PI-RADS 5, 24% of PI-RADS 4 and 6% of PI-RADS
2 lesions, suggesting that high-grade MRI lesions are
related to more aggressive tumours with cribriform
morphology. Prendeville et al.23 identified cribriform
morphology in 8% of PI-RADS 3/4 lesions and in
39% of PI-RADS 5 lesions, indicating that PI-RADS
score might be a predictor for cribriform-positive pros-
tate cancer. In this study we showed that 56% of
false-negative biopsies had a PI-RADS 5 lesion com-
pared to 27% of true-negative biopsies. However, due
to the small number of patients who had undergone
MRI, PI-RADS score was not a predictor for cribri-
form architecture in logistic regression analysis.
We were not able to find any predictive value of
biopsy percentage Gleason pattern 4 or glomeruloid
growth pattern for cribriform architecture on radical
prostatectomy. The presence of cribriform architec-
ture has been associated with higher percentage Glea-
son pattern 4 on biopsies. In a cohort of 370 biopsy
grade group 2 prostate cancer patients, we found
cribriform architecture in 6% of men with <10%
Gleason pattern 4, in 22% of men with 10–25% pat-
tern 4 and in 44% of men with 25–50% pattern 4.7
Nevertheless, biopsy percentage Gleason pattern 4
was not predictive for cribriform architecture in false-
negative biopsies. This paradoxical outcome could be
explained by the low level of concordance between
percentage Gleason pattern 4 on biopsy and matched
radical prostatectomy specimens in this study. Simi-
larly, glomeruloid Gleason pattern 4, which has been
hypothesised to represent a precursor lesion of cribri-
form growth, was not associated with cribriform
architecture in false-negative biopsies.16
Among patients with cribriform architecture, those
with large expansive cribriform fields have the worst
outcome.4 The false-negative rate of 27% for the
large cribriform pattern is significantly less than the
rate of 52% for overall cribriform morphology. As
44% of true-positive biopsies had large cribriform
fields on radical prostatectomy compared to only 15%
of false-negative biopsies, this might explain the sig-
nificantly better biochemical recurrence-free survival
of false-negative biopsies compared to true-positive
biopsies, in addition to other clinicopathological con-
founding factors.
The strong points of this study are the detailed his-
tological review of matched biopsies and radical
prostatectomies. The study is, however, limited by its
low number of patients, the heterogeneity of the
study population, including both patients with first-
time diagnosis and progression during active surveil-
lance, and variability of diagnostic work-up encom-
passing systematic and/or targeted biopsies, as well
as multiparametric MRI assessment. Finally, follow-
up is relatively short, with a median of 27 months.
In conclusion, we demonstrate that 40% of men
with biopsy grade group 2 prostate cancer were false-
negative for invasive cribriform and/or intraductal car-
cinoma. Age and PSA were independent predictors for
cribriform architecture in false-negative biopsies, while
patients with false-negative biopsies more frequently
had PI-RADS score 5 lesions than men with true-nega-
tive biopsies. Multimodal evaluation of biopsy grade
group 2 prostate cancer patients could therefore iden-
tify men with true cribriform-negative biopsies who
might become eligible for active surveillance.
© 2019 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 75, 338–345.
344 E Hollemans et al.
Acknowledgement
This study was supported by a generous grant from
the Jaap Schouten Foundation.
Conflict of Interests
The authors declare no conflicts of interest.
References
1. Kweldam CF, Kummerlin IP, Nieboer D et al. Disease-specific
survival of patients with invasive cribriform and intraductal
prostate cancer at diagnostic biopsy. Mod. Pathol. 2016; 29;
630–636.
2. Truong M, Frye T, Messing E et al. Historical and contempo-
rary perspectives on cribriform morphology in prostate cancer.
Nat. Rev. Urol. 2018; 15; 475–482.
3. Kir G, Sarbay BC, Gumus E et al. The association of the cribri-
form pattern with outcome for prostatic adenocarcinomas.
Pathol. Res. Pract. 2014; 210; 640–644.
4. Hollemans E, Verhoef EI, Bangma CH et al. Large cribriform
growth pattern identifies ISUP grade 2 prostate cancer at high
risk for recurrence and metastasis. Mod. Pathol. 2019; 32;
139–146.
5. Dong F, Yang P, Wang C et al. Architectural heterogeneity and
cribriform pattern predict adverse clinical outcome for Gleason
grade 4 prostatic adenocarcinoma. Am. J. Surg. Pathol. 2013;
37; 1855–1861.
6. Trudel D, Downes MR, Sykes J et al. Prognostic impact of intra-
ductal carcinoma and large cribriform carcinoma architecture
after prostatectomy in a contemporary cohort. Eur. J. Cancer
2014; 50; 1610–1616.
7. Kweldam CF, Kummerlin IP, Nieboer D et al. Presence of inva-
sive cribriform or intraductal growth at biopsy outperforms
percentage grade 4 in predicting outcome of Gleason score
3+4 = 7 prostate cancer. Mod. Pathol. 2017; 30; 1126–1132.
8. Kweldam CF, Wildhagen MF, Steyerberg EW et al. Cribriform
growth is highly predictive for postoperative metastasis and dis-
ease-specific death in Gleason score 7 prostate cancer. Mod.
Pathol. 2015; 28; 457–464.
9. Kweldam CF, Kummerlin IP, Nieboer D et al. Prostate cancer
outcomes of men with biopsy Gleason score 6 and 7 without
cribriform or intraductal carcinoma. Eur. J. Cancer 2016; 66;
26–33.
10. Sauter G, Steurer S, Clauditz TS et al. Clinical utility of quanti-
tative Gleason grading in prostate biopsies and prostatectomy
specimens. Eur. Urol. 2016; 69; 592–598.
11. Corcoran NM, Hovens CM, Hong MK et al. Underestimation of
Gleason score at prostate biopsy reflects sampling error in
lower volume tumours. BJU Int. 2012; 109; 660–664.
12. Kim KH, Lim SK, Shin TY et al. Upgrading of Gleason score
and prostate volume: a clinicopathological analysis. BJU Int.
2013; 111; 1310–1316.
13. Weinreb JC, Barentsz JO, Choyke PL et al. PI-RADS Prostate
imaging – reporting and data system: 2015, version 2. Eur.
Urol. 2016; 69; 16–40.
14. Epstein JI, Egevad L, The Amin MB et al. 2014 International
Society of Urological Pathology (ISUP) Consensus Conference
on Gleason Grading of Prostatic Carcinoma: definition of grad-
ing patterns and proposal for a new grading system. Am. J.
Surg. Pathol. 2016; 40; 244–252.
15. Buyyounouski MK, Choyke PL, McKenney JK et al. Prostate
cancer – major changes in the American Joint Committee on
Cancer eighth edition cancer staging manual. CA Cancer J.
Clin. 2017; 67; 245–253.
16. Lotan TL, Epstein JI. Gleason grading of prostatic adenocarci-
noma with glomeruloid features on needle biopsy. Hum. Pathol.
2009; 40; 471–477.
17. Corcoran NM, Hong MK, Casey RG et al. Upgrade in Gleason
score between prostate biopsies and pathology following radi-
cal prostatectomy significantly impacts upon the risk of bio-
chemical recurrence. BJU Int. 2011; 108; E202–E210.
18. Epstein JI, Feng Z, Trock BJ et al. Upgrading and downgrading
of prostate cancer from biopsy to radical prostatectomy: inci-
dence and predictive factors using the modified Gleason grad-
ing system and factoring in tertiary grades. Eur. Urol. 2012;
61; 1019–1024.
19. Masoomian M, Downes MR, Sweet J et al. Concordance of
biopsy and prostatectomy diagnosis of intraductal and cribri-
form carcinoma in a prospectively collected data set.
Histopathology 2019; 74; 474–482.
20. Amin MB, Lin DW, Gore JL et al. The critical role of the
pathologist in determining eligibility for active surveillance as
a management option in patients with prostate cancer: con-
sensus statement with recommendations supported by the Col-
lege of American Pathologists, International Society of
Urological Pathology, Association of Directors of Anatomic and
Surgical Pathology, the New Zealand Society of Pathologists,
and the Prostate Cancer Foundation. Arch. Pathol. Lab. Med.
2014; 138; 1387–1405.
21. Montironi R, Hammond EH, Lin DW et al. Consensus state-
ment with recommendations on active surveillance inclusion
criteria and definition of progression in men with localized
prostate cancer: the critical role of the pathologist. Virchows
Arch. 2014; 465; 623–628.
22. Truong M, Feng C, Hollenberg G et al. A comprehensive analy-
sis of cribriform morphology on magnetic resonance imaging/
ultrasound fusion biopsy correlated with radical prostatectomy
specimens. J. Urol. 2018; 199; 106–113.
23. Prendeville S, Gertner M, Maganti M et al. Role of magnetic
resonance imaging targeted biopsy in detection of prostate
cancer harboring adverse pathological features of intraductal
carcinoma and invasive cribriform carcinoma. J. Urol. 2018;
200; 104–113.
© 2019 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 75, 338–345.
Prostate cribriform architecture concordance 345
